According to Gram Research analysis, Calculus Bovis, a traditional medicine made from animal gallstones, significantly reduced liver damage and scarring in mice with primary sclerosing cholangitis by restoring normal bile acid and fat levels through activation of specific liver proteins. The treatment worked as well as or better than the standard medication in animal studies, though human clinical trials are still needed to confirm safety and effectiveness in PSC patients.
Researchers tested a traditional Chinese medicine called Calculus Bovis, made from animal gallstones, to see if it could help treat primary sclerosing cholangitis (PSC), a serious liver disease with no FDA-approved cure. In mouse studies, the medicine reduced liver damage, improved how the intestines work, and fixed problems with bile acids and fats in the body. The treatment worked by activating special proteins that help the liver and intestines process bile and fats more efficiently. These findings suggest Calculus Bovis could become a new treatment option for PSC patients, though human studies are still needed.
Key Statistics
A 2026 research study found that Calculus Bovis treatment significantly alleviated liver injury, fibrosis, and intestinal barrier damage in mice with primary sclerosing cholangitis, restoring normal bile acid profiles and reducing abnormal bile acid accumulation in serum and liver tissue.
Research published in 2026 showed that Calculus Bovis ameliorated dyslipidemia in PSC-model mice by reducing both hepatic and serum lipid levels through dual activation of the SIRT1-PGC-1α pathway and direct activation of FXR and PPARα proteins.
A 2026 study demonstrated that Calculus Bovis increased bile acid excretion in feces while normalizing aberrant bile acid profiles across the gut-liver axis in mice with experimental primary sclerosing cholangitis.
The Quick Take
- What they studied: Whether a traditional medicine made from gallstones (Calculus Bovis) could treat primary sclerosing cholangitis, a progressive liver disease that damages bile ducts and currently has no FDA-approved treatment.
- Who participated: Laboratory mice that were given a special diet to develop PSC-like liver disease. The mice were then treated with different doses of Calculus Bovis or a standard liver medication for comparison.
- Key finding: Calculus Bovis significantly reduced liver damage, scarring, and intestinal problems in mice with PSC. It also restored normal bile acid and fat levels, working as well as or better than the standard treatment.
- What it means for you: This research suggests Calculus Bovis could become a new treatment option for PSC patients, but human clinical trials are needed before doctors can prescribe it. People with PSC should discuss this research with their hepatologist but shouldn’t change their current treatment without medical guidance.
The Research Details
Researchers created a mouse model of primary sclerosing cholangitis by feeding mice a special diet that damages the liver in ways similar to human PSC. They then treated different groups of mice with Calculus Bovis at three different doses, compared it to a standard liver medication (UDCA), and measured how well each treatment worked.
The scientists examined multiple aspects of liver health: how much liver damage occurred, whether scarring developed, whether the intestinal barrier (which controls what enters the bloodstream) stayed intact, and whether bile acids and fats returned to normal levels. They also studied which genes and proteins were activated by the treatment to understand exactly how Calculus Bovis works.
The research combined several advanced techniques: genetic analysis to see which genes were turned on or off, computer network analysis to map how different biological pathways connect, and laboratory tests using actual patient blood serum to confirm the findings worked in human biological material.
Using animal models allows researchers to test treatments in a controlled way before attempting human trials. This approach is especially important for rare diseases like PSC where finding enough patients for early studies is difficult. The combination of multiple testing methods—genetic, protein, and functional studies—provides strong evidence that the treatment works through specific biological mechanisms rather than by chance.
The study used multiple complementary research methods (transcriptomics, network pharmacology, and serum pharmacology) which strengthens confidence in the findings. Testing three different doses of Calculus Bovis allowed researchers to identify the most effective amount. The comparison to a standard medication (UDCA) provides a meaningful benchmark. However, this is animal research, so results may not translate directly to humans. The study was published in 2026, making it very recent research.
What the Results Show
Calculus Bovis treatment significantly reduced liver injury and scarring in mice with PSC. The medicine restored normal bile acid levels throughout the gut-liver axis—the connected system where the liver makes bile, the intestines absorb it, and it cycles back to the liver. Mice treated with Calculus Bovis had more bile acids excreted in their feces (which is healthy) and fewer abnormal bile acids building up in their blood and liver tissue.
The treatment also fixed fat metabolism problems. Mice receiving Calculus Bovis had lower fat levels in both their liver and bloodstream, which is important because abnormal fat accumulation contributes to liver damage in PSC. The intestinal barrier—a protective layer that controls what enters the bloodstream—was also repaired by the treatment.
All these improvements occurred at multiple dose levels tested (50, 100, and 150 mg/kg/day), suggesting the treatment has a consistent effect. The results were comparable to or better than the standard PSC medication (UDCA) that was used as a comparison.
The research identified the specific biological mechanisms behind Calculus Bovis’s benefits. The treatment activated a protein called SIRT1, which then activated another protein called PGC-1α. This activation turned on two important liver and intestinal proteins: FXR and PPARα. These proteins are like master switches that control genes involved in bile acid processing and fat burning. Additionally, Calculus Bovis and its active components directly activated FXR and PPARα proteins, creating a dual mechanism of action. When researchers blocked SIRT1 or these receptor proteins in laboratory tests, the protective effects disappeared, confirming these pathways are essential for the treatment’s benefits.
Primary sclerosing cholangitis currently has no FDA-approved treatment, making any effective therapy significant. The standard care is ursodeoxycholic acid (UDCA), which helps some patients but doesn’t stop disease progression in most cases. This research shows Calculus Bovis works through different biological pathways than UDCA, suggesting it could complement existing treatments or work for patients who don’t respond to current options. The dual-mechanism approach (activating both the SIRT1 pathway and directly activating FXR/PPARα) is novel and may explain why it appears more effective than single-target treatments.
This study used mice, not humans, so results may not translate directly to PSC patients. The exact dose that would work in humans is unknown. The research doesn’t show long-term effects or whether benefits persist after treatment stops. The specific active compounds in Calculus Bovis responsible for the benefits weren’t fully isolated and tested individually. Human clinical trials are needed to confirm safety and effectiveness in actual PSC patients. The study doesn’t address potential side effects or drug interactions that might occur in humans.
The Bottom Line
Based on this research, Calculus Bovis shows strong promise as a potential PSC treatment (high confidence in animal models, but low confidence for human application until clinical trials are completed). Current PSC patients should continue their prescribed treatments and discuss this research with their hepatologist. People interested in Calculus Bovis should not self-treat, as the appropriate human dose, safety profile, and potential interactions with other medications remain unknown.
This research is most relevant to people with primary sclerosing cholangitis and their doctors, as it offers hope for a new treatment option. Researchers studying liver disease, bile acid metabolism, and traditional medicine mechanisms should also find this work valuable. People with other cholestatic liver diseases may eventually benefit if human trials prove successful. People without liver disease don’t need to take action based on this research.
In the mouse studies, significant improvements appeared within 4 weeks of treatment. If human trials proceed, it typically takes 3-5 years to complete Phase 1 and Phase 2 trials to establish safety and initial effectiveness. Full FDA approval could take 5-10 years from the start of human testing. PSC patients should not expect this treatment to become available immediately but may see it as a treatment option within the next 5-10 years if clinical trials are successful.
Frequently Asked Questions
What is Calculus Bovis and how is it made?
Calculus Bovis is a traditional Chinese medicine derived from animal gallstones, historically used to treat liver and bile duct diseases. The gallstones are processed and refined into a medicinal form containing bioactive compounds that affect how the body processes bile acids and fats.
Can I take Calculus Bovis if I have primary sclerosing cholangitis?
Not yet—this research is from animal studies only. Calculus Bovis is not FDA-approved for PSC treatment. Discuss this research with your hepatologist, but continue your current prescribed treatment. Human clinical trials are needed before doctors can recommend it for PSC patients.
How does Calculus Bovis treat liver disease differently than current medications?
Calculus Bovis works through a dual mechanism: it activates the SIRT1 protein pathway while also directly activating FXR and PPARα proteins. This dual approach enhances bile acid detoxification and fat burning more comprehensively than single-target medications like UDCA.
When will Calculus Bovis be available as a PSC treatment?
If human clinical trials begin soon and are successful, Calculus Bovis could potentially become available as a treatment option within 5-10 years. Currently, it remains a research compound without FDA approval for PSC treatment.
Are there side effects or risks from Calculus Bovis?
This animal study didn’t report side effects, but human safety data doesn’t exist yet. Any new treatment requires extensive safety testing in humans before approval. Discuss potential risks and benefits with your doctor before considering any new therapy.
Want to Apply This Research?
- Track liver enzyme levels (ALT, AST, bilirubin) monthly if you have PSC, noting any changes in relation to treatment adjustments. Record symptom severity on a 1-10 scale weekly, including fatigue, itching, and abdominal discomfort.
- If prescribed Calculus Bovis in future clinical settings, set daily reminders to take the medication at consistent times. Log each dose taken and any side effects or symptom changes in the app to share with your hepatologist at appointments.
- Establish a baseline of your current liver function tests and symptoms before any new treatment begins. Schedule quarterly check-ins with your doctor to review app-tracked data and lab results. Monitor for changes in stool color, urine color, or itching intensity, which may indicate changes in bile flow.
This article discusses research findings from animal studies and does not constitute medical advice. Primary sclerosing cholangitis is a serious medical condition requiring professional diagnosis and treatment. Calculus Bovis is not FDA-approved for treating PSC and should not be used to replace prescribed medications without explicit medical guidance. Anyone with PSC or considering any new treatment should consult with their hepatologist or gastroenterologist before making changes to their treatment plan. This research is preliminary and human clinical trials are needed before Calculus Bovis can be recommended for patient use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.